BridgeBio reports BBO-8520 response data, cash runway into 2028
BridgeBio said BBO-8520 plus pembrolizumab showed a 75% ORR at 500 mg QD, 53% across doses, and monotherapy produced a 63% ORR. It also said cash runway was $344.1 million into 2028.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.